Clinical Trial Update: A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating LAG-3 and PD-1 therapies with or without TIGIT, compared to PD-L1 therapy, in untreated locally advanced/metastatic urothelial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)
• Relatlimab (relatlimab)
• Tiragolumab (tiragolumab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Urothelial Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING